A few “sleeper” provisions in the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (“the Act”) authorize financial incentives for whistleblowers who provide original information to the U.S. Securities and Exchange Commission (“SEC”) or U.S. Commodity Futures Trading Commission (“CFTC”). These measures increase the enforcement and litigation risks and the compliance costs for publicly traded companies, including large healthcare providers such as pharmaceutical companies. Hundreds of tips have been pouring in, although the SEC has yet to issue the implementing rules and regulations.
As one plaintiff’s attorney has remarked, the Act offers a “trifecta of enticements” for would-be whistleblowers who can report violations anonymously, enjoy heightened protections from retaliation—and now have a direct federal cause of action for the recovery of twice back pay, with interest, reasonable attorneys’ fees and litigation costs—and be paid between 10 percent and 30 percent of the amount collected over $1 million.
Employees of a company are not the only potential whistleblowers. They may be joint-venture partners, contractors, sales agents or almost anyone who can provide original information, including analysis of public information. And they may be affiliated with a privately held or foreign business subsidiary consolidated in the company’s balance sheet. Under the law and the implementing regulations proposed on November 3, 2010, only a few categories generally won’t qualify, such as...
Please see full alert below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.